NEDD9 overexpression: Prognostic and guidance value in acute myeloid leukaemia

Abstract

Acute myeloid leukaemia (AML) is a blood cancer characterized by clonal myeloid precursors in bone marrow (BM), leading to haematopoiesis failure. 1 Clinical outcome of AML is highly heterogeneous, survive time from days to cure. 1 Cytogenetic abnormalities and gene mutations obtained at the diagnosis time provide the most important information. 2 Recently, aberrant gene expression has also been found to be associated with prognosis in AML, such as BAALC, MN1, ERG, and WT1. 3 Therefore, identification of newly developed biomarkers and construction of molecular-based prognostic risk scores could more precisely recognize the patients who are at high risk, and finally give intensive treatment to improve their clinical outcome.

Distinct associations of NEDD4L expression with genetic abnormalities and prognosis in acute myeloid leukemia

“…Underexpression of NEDD4L was observed to be correlated with normal karyotype, FLT3 and NPM1 mutations, but negatively associated with complex karyotype and TP53 mutations. Notably, a recent study also showed that abnormal NEDD9 expression, a member of NEDD family, was highly correlated with specific French-American-British (FAB) subtypes and karyotypes as well as genetic mutations, which was similar to our results [ 37 ]. These results together disclosed that NEDD4L underexpression play a key role in CN-AML biology caused by genetic mutations.…”

Retracted: METTL3 enhances the effect of YTHDF1 on NEDD1 mRNA stability by m6A modification in diffuse large B‐cell lymphoma cells

“…8 Moreover, NEDD9 overexpression was related to genetic abnormalities and prognosis and might serve as a possible biomarker guiding the choice between hematopoietic stem cell transplantation and chemotherapy in patients with acute myeloid leukemia after achieving complete remission. 9 However, there is little evidence showing the direct linkage between NEDD1 overexpression and the development of DLBCL. Critically, the N6methyladenosine (m6A)-based prognostic signature has been reported to be a prognostic predictor for DLBCL, and immune microenvironment governed by m6A might be a part of the mechanism.…”

“…Neural precursor cell expressed developmentally downregulated protein 1 (NEDD1) localizes to the centrosome and mitotic spindle, and the localization of key centrosomal proteins is imperative in preventing cells against uncontrolled growth and the development of cancers, suggesting that NEDD1 might be a possible candidate for anticancer treatment 8 . Moreover, NEDD9 overexpression was related to genetic abnormalities and prognosis and might serve as a possible biomarker guiding the choice between hematopoietic stem cell transplantation and chemotherapy in patients with acute myeloid leukemia after achieving complete remission 9 . However, there is little evidence showing the direct linkage between NEDD1 overexpression and the development of DLBCL.…”

Busca De Marcadores Moleculares Preditivos Do Acometimento De Linfonodos Em Carcinomas Papilíferos De Tireoide

“…Embora a expressão deste gene esteja relacionada a um pior prognóstico, e desenvolvimento de metástases em vários tipos de cânceres, tais como tumores de mama (Bemmerlein et al 2022), colorretal (Meng et al, 2019), pâncreas (Xue et al, 2021), renal (Ledinsky Opačić et al, 2019, estômago (Zhang et al, 2019), pulmão (Deneka et al 2021) e hepatocelular (Zhou et al, 2017), no presente estudo não foi observada a sua relação com o desenvolvimento e predição do envolvimento de linfonodos nos tumores de tireoide. O papel do gene NEDD9 tem sido determinante em uma progressão desfavorável de muitos tumores, mostrado inclusive por estudos que relacionaram a elevada expressão desse gene com resistência à quimioterápicos, e sobrevida reduzida (Hua et al 2021).…”